Search

Your search keyword '"Schmalzing, Marc"' showing total 146 results
Start Over Author "Schmalzing, Marc" Search Limiters Peer Reviewed
146 results on '"Schmalzing, Marc"'

2. Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network

Author

Strunz, Patrick-Pascal, Englbrecht, Matthias, Risser, Linus Maximilian, Witte, Torsten, Froehlich, Matthias, Schmalzing, Marc, Gernert, Michael, Schmieder, Astrid, Bartz-Bazzanella, Peter, von der Decken, Cay, Karberg, Kirsten, Gauler, Georg, Wurth, Patrick, Späthling-Mestekemper, Susanna, Kuhn, Christoph, Vorbrüggen, Wolfgang, Heck, Johannes, Welcker, Martin, and Kleinert, Stefan

Published
2024
Full Text
View/download PDF

4. The exercise-app Axia for axial spondyloarthritis enhances the home-based exercise frequency in axial spondyloarthritis patients – A cross-sectional survey

Author

Strunz, Patrick-Pascal, Le Maire, Maxime, Heusinger, Tobias, Klein, Juliana, Labinsky, Hannah, Fleischer, Anna, Luetkens, Karsten Sebastian, Possler, Patricia, Gernert, Michael, Leppich, Robert, Schmieder, Astrid, Hammel, Ludwig, Schulz, Evelin, Sperlich, Billy, Froehlich, Matthias, and Schmalzing, Marc

Published
2024
Full Text
View/download PDF

7. Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study

Author

Schmalzing, Marc, Kellner, Herbert, Askari, Ayman, De Toro Santos, Javier, Vazquez Perez-Coleman, Julio Cesar, Foti, Rosario, Jeka, Sławomir, Haraoui, Boulos, Allanore, Yannick, Peichl, Peter, Oehri, Martin, Rahman, Masiur, Furlan, Fabricio, Romero, Elisa, Hachaichi, Sohaib, Both, Charlotte, Brueckmann, Ines, and Sheeran, Tom

Published
2024
Full Text
View/download PDF

8. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study

Author

Maid, Pablo, Rillo, Oscar, Inderjeeth, Charles, Scheinecker, Clemens, Hermann, Josef, Marcolino, Flora Maria D'Andrea, Dias, Laiza H, Scafuto, Antonio, Bookman, Arthur AM, Fortin, Isabelle, Morin, Frederic, Goio, Elizabeth Jean Moreno, Pezo Ruiz, Ninette, Roman Zamoran, Carlos Patricio, Gonzalez Abarzua, Ivan Antonio, Elgueta, Sergio Fabian, Forero Illera, Elias Gonzalo, Marquez Herndez, Javier Dario, Garcia, Alex Echeverri, Pensec, Valerie Devauchelle, Hachulla, Eric, Mariette, Xavier, Gottenberg, Jacques-Eric, Le Guern, Veronique, Finzel, Stephanie, Schaefer, Valentin, Tony, Hans-Peter, Thomas Schmalzing, Marc, Tausche-Wunderlich, Anne-Kathrin, Tzioufas, Athanasios, Balog, Attila, Rojkovich, Bernadette, Varga, Tunde, Lidar, Merav, Rosner, Itzhak, Levy, Yair, Dagna, Lorenzo, Mosca, Marta, Quartuccio, Luca, Nishiyama, Susumu, Kodera, Masanari, Kaneko, Yuko, Okada, Masato, Ueki, Yukitaka, Hwan Park, Sung, van Daele, Paulus Leon Arthur, Bootsma, Hendrika, Duarte Barcelos, Filipe Alexandre, Crispim Romao, Vasco Madeira, Raimundo Vinagre, Filipe Manuel, Tavaresda Costa, Jose Antonio, Rednic, Simona, Duca, Liliana, Maslyanskiy, Alexey, Yakupova, Svetlana, Bugrova, Olga, Izmozherova, Nadezhda, Zotkin, Evgenyi, Nikolaevna Anoshenkova, Olga, Kvarnstrom, Marika, Tufan, Abdurrahman, Fisher, Benjamin, Yee, Chee Seng, Parker, Benjamin Joseph, Grader Beck, Thomas, Lawrence Ford, Theresa, Papas, Athena, Carsons, Steven, Thiagarajan, Saravanan, Zero, Domenick, McCoy, Sara, Sandorfi, Nora, Fisher, Benjamin A, Grader-Beck, Thomas, Ng, Wan-Fai, van Daele, P L A, Noaiseh, Ghaith, Elgueta, Sergio, McCoy, Sara S, Akpek, Esen, Bookman, Arthur, Sopala, Monika, Montecchi-Palmer, Michela, Luo, Wen-Lin, Scheurer, Cornelia, and Hueber, Wolfgang

Published
2024
Full Text
View/download PDF

10. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis

Author

Moinzadeh, Pia, Bonella, Francesco, Oberste, Max, Weliwitage, Jithmi, Blank, Nobert, Riemekasten, Gabriela, Müller-Ladner, Ulf, Henes, Jörg, Siegert, Elise, Günther, Claudia, Kötter, Ina, Pfeiffer, Christiane, Schmalzing, Marc, Zeidler, Gabriele, Korsten, Peter, Susok, Laura, Juche, Aaron, Worm, Margitta, Jandova, Ilona, Ehrchen, Jan, Sunderkötter, Cord, Keyßer, Gernot, Ramming, Andreas, Schmeiser, Tim, Kreuter, Alexander, Lorenz, Hanns-Martin, Hunzelmann, Nicolas, and Kreuter, Michael

Published
2024
Full Text
View/download PDF

13. The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease

Author

Smits, Bas, Goldacker, Sigune, Seneviratne, Suranjith, Malphettes, Marion, Longhurst, Hilary, Mohamed, Omar E., Witt-Rautenberg, Carla, Leeman, Lucy, Schwaneck, Eva, Raymond, Isabelle, Meghit, Kilifa, Uhlmann, Annette, Winterhalter, Christine, van Montfrans, Joris, Klima, Marion, Workman, Sarita, Fieschi, Claire, Lorenzo, Lorena, Boyle, Sonja, Onyango-Odera, Shamin, Price, Suzanne, Schmalzing, Marc, Aurillac, Valerie, Prasse, Antje, Hartmann, Ieneke, Meerburg, Jennifer J., Kemner-van de Corput, Mariette, Tiddens, Harm, Grimbacher, Bodo, Kelleher, Peter, Patel, Smita Y., Korganow, Anne-Sophie, Viallard, Jean-Francois, Tony, Hans-Peter, Bethune, Claire, Schulze-Koops, Hendrik, Witte, Torsten, Huissoon, Aarnoud, Baxendale, Helen, Grigoriadou, Sofia, Oksenhendler, Eric, Burns, Siobhan O., and Warnatz, Klaus

Published
2023
Full Text
View/download PDF

15. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force

Author

Cuvelier, Geoffrey D.E., Schoettler, Michelle, Buxbaum, Nataliya P., Pinal-Fernandez, Iago, Schmalzing, Marc, Distler, Jörg H.W., Penack, Olaf, Santomasso, Bianca D., Zeiser, Robert, Angstwurm, Klemens, MacDonald, Kelli P.A., Kimberly, W. Taylor, Taylor, Naomi, Bilic, Ervina, Banas, Bernhard, Buettner-Herold, Maike, Sinha, Namita, Greinix, Hildegard T., Pidala, Joseph, Schultz, Kirk R., Williams, Kirsten M., Inamoto, Yoshihiro, Cutler, Corey, Griffith, Linda M., Lee, Stephanie J., Sarantopoulos, Stefanie, Pavletic, Steven Z., and Wolff, Daniel

Published
2022
Full Text
View/download PDF

17. Autologous hematopoietic stem cell transplantation improves long-term survival—data from a national registry

Author

Blank, Norbert, Schmalzing, Marc, Moinzadeh, Pia, Oberste, Max, Siegert, Elise, Müller-Ladner, Ulf, Riemekasten, Gabriela, Günther, Claudia, Kötter, Ina, Zeidler, Gabriele, Pfeiffer, Christiane, Juche, Aaron, Jandova, Ilona, Ehrchen, Jan, Susok, Laura, Schmeiser, Tim, Sunderkötter, Cord, Distler, Jörg H. W., Worm, Margitta, Kreuter, Alexander, Keyßer, Gernot, Lorenz, Hanns-Martin, Krieg, Thomas, Hunzelmann, Nicolas, and Henes, Jörg

Published
2022
Full Text
View/download PDF

19. MRVAS—introducing a standardized magnetic resonance scoring system for assessing the extent of inflammatory burden in giant cell arteritis.

Author

Froehlich, Matthias, Guggenberger, Konstanze V, Vogt, Marius, Mihatsch, Patrick W, Torre, Giulia Dalla, Werner, Rudolf A, Gernert, Michael, Strunz, Patrick P, Portegys, Jan, Weng, Andreas M, Schmalzing, Marc, and Bley, Thorsten A

Abstract

Objectives Our aim was to introduce a standardized system for assessing the extent of GCA on MRI, i.e. the Magnetic Resonance Vasculitis Activity Score (MRVAS). To obtain a comprehensive view, we used an extensive MRI protocol including cranial vessels and the aorta with its branches. To test reliability, MRI was assessed by four readers with different levels of experience. Methods A total of 80 patients with suspected GCA underwent MRI of the cranial arteries and the aorta and its branches (20 vessel segments). Every vessel was rated dichotomous [inflamed (coded as 1) or not (coded as 0)], providing a summed score of 0–20. Blinded readers [two experienced radiologists (ExR) and two inexperienced radiologists (InR)] applied the MRVAS on an individual vessel and an overall level (defined as the highest score of any of the individual vessel scores). To determine interrater agreement, Cohen's κ was calculated for pairwise comparison of each reader for individual vessel segments. Intraclass correlation coefficients (ICCs) were used for the MRVAS. Results Concordance rates were excellent for both subcohorts on an individual vessel-based (GCA: ICC 0.95; non-GCA: ICC 0.96) and overall MRVAS level (GCA: ICC 0.96; non-GCA: ICC 1.0). Interrater agreement yielded significant concordance (P  < 0.001) for all pairs (κ range 0.78–0.98). No significant differences between ExRs and InRs were observed (P  = 0.38). Conclusion The proposed MRVAS allows standardized scoring of inflammation in GCA and achieved high agreement rates in a prospective setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study.

Author

Strunz, Patrick-Pascal, Risser, Linus Maximilian, Englbrecht, Matthias, Witte, Torsten, Froehlich, Matthias, Schmalzing, Marc, Gernert, Michael, Hueper, Sebastian, Bartz-Bazzanella, Peter, von der Decken, Cay, Karberg, Kirsten, Gauler, Georg, Späthling-Mestekemper, Susanna, Kuhn, Christoph, Vorbrüggen, Wolfgang, Welcker, Martin, and Kleinert, Stefan

Subjects
INTERLEUKIN-6 receptors, TUMOR necrosis factors, THROMBOEMBOLISM, RHEUMATOID arthritis, KINASE inhibitors, RHEUMATOLOGISTS
Abstract

Background: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence treatment patterns for rheumatoid arthritis (RA) drugs, but little is known about the impact of these recommendations in routine clinical care. Methods: We retrospectively analyzed the German RHADAR rheumatology database for adult patients with RA and documentation of a new therapy with a JAKi, tumor necrosis factor inhibitor (TNFi), or interleukin-6 receptor inhibitor (IL-6Ri). Data were grouped into half-yearly intervals from quarter (Q)2/2020 to Q3/2023. The period from Q4/2022 to Q1/2023 immediately followed the initial EMA endorsement of Pharmacovigilance Risk Assessment Committee (PRAC) recommendations and Q2/2023-Q3/2023 immediately followed the direct healthcare provider communication (DHPC) containing the new safety JAKi recommendations. Results: Between April 1, 2020 and September 23, 2023, 3008 newly initiated therapies for TNFi (1499 [49.8%]), JAKi (1126 [37.4%]), and IL-6Ri (383 [12.7%]) were documented by the treating physicians. JAKi were increasingly used in the first two half-year periods (from 29.7% of these therapies in Q2/2020-Q3/2020 to 46.7% in Q2/2021-Q3/2021; odds ratio [OR] 2.08; p<0.001). The proportion of initiated JAKi therapies decreased significantly after the PRAC recommendations (32.9%; OR vs peak 0.56; p=0.001) and the DHPC letter (26.1%; OR vs peak 0.40; p<0.001). JAKi were more likely to be used as >3rd-line therapy in later time periods. Conclusions: This exploratory study suggests that EMA safety recommendations for JAKi influenced treatment patterns of RA patients who received JAKi in Germany. Additional studies will be needed to confirm these findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations

Author

Boztug, Kaan, Brunner, Juergen, Demel, Ulrike F., Förster-Waldl, Elisabeth, Gasteiger, Lukas M., Göschl, Lisa, Kojić, Marina, Schroll, Andrea, Seidel, Markus G., Wintergerst, Uwe, Wisgrill, Lukas, Sharapova, Svetlana O., Goffard, Jean-Christophe, Kerre, Tessa, Meyts, Isabelle, Roosens, Fine, Smet, Julie, Haerynck, Filomeen, Eric, Zelimir Pavle, Milenova, Veneta, Gagro, Alenka, Richter, Darko, Chovancova, Zita, Hlavackova, Eva, Litzman, Jiri, Milota, Tomas, Sediva, Anna, Elaziz, Dalia Abd, Alkady, Radwa Salaheldin, El Sayed El Hawary, Rabab, Eldash, Alia S., Galal, Nermeen, Lotfy, Sohilla, Meshaal, Safa S., Reda, Shereen M., Sobh, Ali, Elmarsafy, Aisha, Seppänen, Mikko R.J., Brosselin, Pauline, Courteille, Virginie, De Vergnes, Nathalie, Kracker, Sven, Pergent, Martine, Randrianomenjanahary, Philippe, Ahrenstorf, Gerrit, Albert, Michael H., Ankermann, Tobias, Atschekzei, Faranaz, Baumann, Ulrich, Becker, Benjamin C., Behrends, Uta, Belohradsky, Bernd H., Biegner, Anika-Kerstin, Binder, Nadine, Bode, Sebastian F.N., Boesecke, Christoph, Boetticher, Benedikt, Borte, Michael, Borte, Stephan, Classen, Carl Friedrich, Dirks, Johannes, Dückers, Gregor, El-Helou, Sabine, Ernst, Diana, Fasshauer, Maria, Fecker, Gisela, Felgentreff, Kerstin, Foell, Dirk, Ghosh, Sujal, Girschick, Hermann J., Goldacker, Sigune, Graf, Norbert, Graf, Dagmar, Greil, Johann, Hanitsch, Leif Gunnar, Hauck, Fabian, Heeg, Maximilian, Heine, Sabine I., Henes, Joerg C., Hoenig, Manfred, Holzer, Ursula, Holzinger, Dirk, Horneff, Gerd, Hundsdoerfer, Patrick, Jablonka, Alexandra, Jakoby, Donate, Joean, Oana, Kaiser-Labusch, Petra, Klemann, Christian, Kobbe, Robin, Körholz, Julia, Kramm, Christof M., Krüger, Renate, Landwehr-Kenzel, Sybille, Lehmberg, Kai, Liese, Johannes G., Lippert, Conrad Ferdinand, Maccari, Maria Elena, Masjosthusmann, Katja, Meinhardt, Andrea, Metzler, Markus, Morbach, Henner, Müller, Ingo, Naumann-Bartsch, Nora, Neubert, Jennifer, Niehues, Tim, Peter, Hans-Hartmut, Rieber, Nikolaus, Ritterbusch, Henrike, Rockstroh, Jürgen Kurt, Roesler, Joachim, Schauer, Uwe, Scheible, Raphael, Schmalzing, Marc, Schmidt, Reinhold Ernst, Schneider, Dominik T., Schreiber, Stefan, Schuetz, Catharina, Schulz, Ansgar, Schulze-Koops, Hendrik, Schulze-Sturm, Ulf, Schuster, Volker, Schwaneck, Eva C., Schwarz, Klaus, Schwarze-Zander, Carolynne, Sirin, Mehtap, Skapenko, Alla, Sogkas, Georgios, Sparber-Sauer, Monika, Speckmann, Carsten, Steinmann, Sandra, Stiehler, Sophie, Tenbrock, Klaus, von Bernuth, Horst, Warnatz, Klaus, Wasmuth, Jan-Christian, Weiss, Michael, Witte, Torsten, Wittke, Kirsten, Wittkowski, Helmut, Zeuner, Rainald A., Farmaki, Evangelia, Hatzistilianou, Maria N., Kakkas, Ioannis, Kanariou, Maria G., Kapousouzi, Androniki, Liatsis, Emmanouil, Maggina, Paraskevi, Papadopoulou-Alataki, Efimia, Raptaki, Maria, Speletas, Matthaios, Tantou, Sofia, Goda, Vera, Kriván, Gergely, Marodi, Laszlo, Abolhassani, Hassan, Aghamohammadi, Asghar, Rezaei, Nima, Feighery, Conleth, Leahy, Timothy Ronan, Ryan, Paul, Batzir, Nurit Assia, Garty, Ben Zion, Tamary, Hannah, Aiuti, Alessandro, Amodio, Donato, Azzari, Chiara, Barzaghi, Federica, Baselli, Lucia A., Cancrini, Caterina, Carrabba, Maria, Cazzaniga, Marco, Cesaro, Simone, Chinello, Matteo, Danieli, Maria Giovanna, Dellepiane, Rosa Maria, Fabio, Giovanna, Gambineri, Eleonora, Lodi, Lorenzo, Lougaris, Vassilios, Marasco, Carolina, Martire, Baldassarre, Marzollo, Antonio, Milito, Cinzia, Moschese, Viviana, Pignata, Claudio, Plebani, Alessandro, Porta, Fulvio, Quinti, Isabella, Ricci, Silvia, Soresina, Annarosa, Tommasini, Alberto, Vacca, Angelo, Vanessa, Clementina, Blažienė, Audra, Sitkauskiene, Brigita, Gowin, Ewelina, Heropolitańska-Pliszka, Edyta, Pietrucha, Barbara, Szaflarska, Anna, Więsik-Szewczyk, Ewa, Wolska-Kuśnierz, Beata, Esteves, Isabel, Faria, Emilia, Marques, Laura Hora, Neves, João Farela, Silva, Susana L., Teixeira, Carla, Pereira da Silva, Sara, Capilna, Brindusa Ruxandra, Guseva, Marina N., Shcherbina, Anna, Bobcakova, Anna, Ciznar, Peter, Gabzdilova, Juliana, Jesenak, Milos, Kapustova, Lenka, Orosova, Jaroslava, Petrovicova, Otilia, Raffac, Stefan, Kopač, Peter, Allende, Luis M., Antolí, Arnau, Blanch, Gemma Rocamora, Carbone, Javier, Dieli-Crimi, Romina, Garcia-Prat, Marina, Gil-Herrera, Juana, Gonzalez-Granado, Luis Ignacio, Agulló, Pilar Llobet, Olbrich, Peter, Parra-Martínez, Alba, Paz-Artal, Estela, Pleguezuelo, Daniel E., Rodríguez, Nerea Salmón, Sánchez-Ramón, Silvia, Santos-Pérez, Juan Luis, Solanich, Xavier, Soler-Palacin, Pere, González-Amores, Miriam, Ekwall, Olov, Fasth, Anders, Bitzenhofer-Grüber, Michaela, Candotti, Fabio, Dimitriou, Florentia, Heininger, Ulrich, Holbro, Andreas, Jandus, Peter, Kolios, Antonios G.A., Marschall, Karin, Schmid, Jana Pachlopnik, Posfay-Barbe, Klara M., Prader, Seraina, Reichenbach, Janine, Steiner, Urs C., Trück, Johannes, Bredius, Robbert G., de Kruijf- Bazen, Suzanne, de Vries, Esther, Henriet, Stefanie S.V., Kuijpers, Taco W., Potjewijd, Judith, Rutgers, Abraham, Stol, Kim, van Aerde, Koen J., Van den Berg, J. Merlijn, van de Ven, Annick A.J.M., Montfrans, Jorisvan, Aydemir, Sezin, Baris, Safa, Dogu, Figen, Ikinciogullari, Aydan, Karakoc-Aydiner, Elif, Kilic, Sara S., Kiykim, Ayca, Kökçü Karadağ, Şefika İlknur, Kutukculer, Necil, Ocak, Suheyla, UNAL, Ekrem, Boyarchuk, Oksana, Hilfanova, Anna, Kostyuchenko, Larysa V., Alachkar, Hana, Arkwright, Peter D., Baxendale, Helen E., Bernatoniene, Jolanta, Coulter, Tanya I., Garcez, Tomaz, Goddard, Sarah, Gompels, Mark M., Grigoriadou, Sofia, Herriot, Richard, Herwadkar, Archana, Huissoon, Aarnoud, Ibberson, Lisa, Nademi, Zoreh, Noorani, Sadia, Parvin, Shahnaz, Steele, Cathal Laurence, Thomas, Moira, Waruiru, Catherine, Yong, Patrick F.K., Bourne, Helen, Thalhammer, Julian, Kindle, Gerhard, Nieters, Alexandra, Rusch, Stephan, Fischer, Alain, Grimbacher, Bodo, Edgar, David, Buckland, Matthew, Mahlaoui, Nizar, and Ehl, Stephan

Published
2021
Full Text
View/download PDF

26. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.

Author

Strunz, Patrick-Pascal, Englbrecht, Matthias, Risser, Linus Maximilian, Witte, Torsten, Froehlich, Matthias, Schmalzing, Marc, Gernert, Michael, Schmieder, Astrid, Bartz-Bazzanella, Peter, von der Decken, Cay, Karberg, Kirsten, Gauler, Georg, Wurth, Patrick, Späthling-Mestekemper, Susanna, Kuhn, Christoph, Vorbrüggen, Wolfgang, Heck, Johannes, Welcker, Martin, and Kleinert, Stefan

Subjects
TUMOR necrosis factors, PSORIATIC arthritis, KINASE inhibitors, DATABASES, INTERLEUKIN-17, ANTIRHEUMATIC agents
Abstract

Objective: Treatment options with disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) have evolved over recent years. In addition to Janus kinase inhibitors (JAKi), four classes of biologic DMARDs (bDMARDs; interleukin [IL]-23 inhibitors [IL-23i], IL-12/23 inhibitors [IL-12/23i], tumor necrosis factor inhibitors [TNFi], and IL-17 inhibitors [IL-17i]) are currently approved for moderate to severe PsA treatment. There is minimal evidence of the persistence of these drugs among PsA outpatients in a real-world scenario during the period following the approval of JAKi. Therefore, we aimed to analyze the drug survival rates of biologic and JAKi therapies among German PsA outpatients during routine clinical care. Methods: We retrospectively analyzed PsA patients with a new prescription for a biologic or JAKi in the RHADAR database between January 2015 and October Results: 1352 new prescriptions with bDMARDs (IL-12/23i [n=50], IL-23i [n=31], TNFi [n=774], IL-17i [n=360]) or JAKi (n=137) were identified. The 5-year drug survival rate was 67.8% for IL-17i, 62.3% for TNFi, 53.3% for JAKi, and 46.0% for IL-12/23i. Discontinuation probabilities for JAKi and IL-12/23i were significantly higher compared with TNFi (JAKi hazard ratio [HR] 1.66, [95% CI 1.23-2.24], p=0.001; IL-12/23i HR 1.54, [95% CI 1.02-2.33], p=0.042) and IL-17i (JAKi HR 1.77, [95% CI 1.27-2.47], p=0.001; IL-12/23i HR 1.64, [95% CI 1.06-2.55], p=0.027). JAKi-treated patients had more severe disease and more osteoarthritis (OA) compared to TNFi and more OA compared to IL-17i. Conclusion: German PsA outpatients might persist longer with TNFi and IL-17i compared with IL-12/23i or JAKi. For TNFi, differences in subgroup characteristics and comorbidities (OA) may have affected drug survival rates. For IL-17i, the longer drug survival might not only be related to less OA compared to JAKi and, therefore, might be affected by other factors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Case Report: Effectiveness of secukinumab in systemic sclerosis with early skin progress after autologous hematopoietic stem cell transplantation and end-stage kidney disease.

Author

Strunz, Patrick-Pascal, Labinsky, Hannah, Nagler, Lea-Kristin, Portegys, Jan, Froehlich, Matthias, Gernert, Michael, and Schmalzing, Marc

Subjects
HEMATOPOIETIC stem cell transplantation, CHRONIC kidney failure, SYSTEMIC scleroderma, KIDNEY transplantation, KIDNEY failure, TREATMENT effectiveness
Abstract

Autologous hematopoietic stem cell transplantation (aHSCT) represents an effective treatment option in patients with severe forms of systemic sclerosis (SSc) by resetting the immune system. Nevertheless, secondary autoimmune disorders and progressive disease after aHSCT might necessitate renewed immunosuppressive treatments. This is particularly challenging when organ dysfunction, i.e., end-stage kidney failure, is present. In this case report, we present the unique case of a 43-year-old female patient with rapidly progressive diffuse systemic sclerosis who underwent aHSCT despite end-stage renal failure as consequence of SSc-renal crisis. Therefore, conditioning chemotherapy was performed with melphalan instead of cyclophosphamide with no occurrence of severe adverse events during the aplastic period and thereafter. After aHSCT, early disease progression of the skin occurred and was successfully treated with secukinumab. Thereby, to the best of our knowledge, we report the first case of successful aHSCT in a SSc-patient with end-stage kidney failure and also the first successful use of an IL-17 inhibitor to treat early disease progression after aHSCT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Student-led clinics and ePROs to accelerate diagnosis and treatment of patients with axial spondyloarthritis: results from a prospective pilot study.

Author

von Rohr, Sophie, Knitza, Johannes, Grahammer, Manuel, Schmalzing, Marc, Kuhn, Sebastian, Schett, Georg, Ramming, Andreas, and Labinsky, Hannah

Subjects
SPONDYLOARTHROPATHIES, LONGITUDINAL method, PILOT projects, PATIENT reported outcome measures, NONSTEROIDAL anti-inflammatory agents
Abstract

We aimed to investigate (1) student-led clinics and (2) electronic patient-reported outcomes (ePROs) to accelerate diagnosis and treatment of patients with axial spondyloarthritis (axSpA). Patients with suspected axSpA completed an initial student-led clinic visit (T-1) prior to their planned actual rheumatologist visit (T0). Acceleration of patient appointment and NSAID therapy start, availability of diagnostic findings, and treatment response at T0 were evaluated. Beginning at T-1, patients completed electronic BASDAI questionnaires every 2 weeks. Concordance of paper-based and electronic BASDAI was evaluated. Patient acceptance of ePRO reporting and student-led clinics was measured using the net promoter score (NPS). 17/36 (47.2%) included patients were diagnosed with axSpA. Student-led clinics (T-1) significantly accelerated patient appointments by more than 2 months (T0, T-1, p < 0.0001) and axSpA guideline-conform NSAID treatment (p < 0.0001). At T0, diagnostic workup was completed for all patients and 7/17 (41.2%) axSpA patients presented with a clinically important improvement or were in remission. 34/36 (94.4%) patients completed at least 80% of the ePROs between T-1 and T0. Electronic and paper-administered BASDAI correlated well (r = 0.8 p < 0.0001). Student-led clinics and ePROs were well accepted by patients with NPS scores of + 62.0% (mean ± SD 9.2/10.0 ± 0.9) and + 30.5% (mean ± SD 8.0/10.0 ± 1.7), respectively. In conclusion, student-led clinics and ePRO monitoring were well accepted, accelerated diagnostic workup and treatment in patients with axSpA. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.

Author

Kreuter, Michael, Bonella, Francesco, Blank, Norbert, Riemekasten, Gabriela, Müller-Ladner, Ulf, Henes, Jörg, Siegert, Elise, Günther, Claudia, Kötter, Ina, Pfeiffer, Christiane, Schmalzing, Marc, Zeidler, Gabriele, Korsten, Peter, Susok, Laura, Juche, Aaron, Worm, Margitta, Jandova, Ilona, Ehrchen, Jan, Sunderkötter, Cord, and Keyßer, Gernot

Subjects
EVALUATION of medical care, CARBON monoxide, CONFIDENCE intervals, INTERSTITIAL lung diseases, SYSTEMIC scleroderma, RETROSPECTIVE studies, GASTROESOPHAGEAL reflux, PROTON pump inhibitors, RISK assessment, VITAL capacity (Respiration), PEARSON correlation (Statistics), CHI-squared test, KAPLAN-Meier estimator, DESCRIPTIVE statistics, PROGRESSION-free survival, OVERALL survival, DISEASE risk factors, DISEASE complications
Abstract

Objectives Gastroesophageal reflux disease (GERD) occurs frequently in patients with SSc. We investigated whether the presence of GERD and/or the use of anti-acid therapy, specifically proton-pump inhibitors (PPIs), are associated with long-term outcomes, especially in SSc-associated interstitial lung disease (SSc-ILD). Methods We retrospectively analysed patients with SSc and SSc-ILD from the German Network for Systemic Sclerosis (DNSS) database (2003 onwards). Kaplan–Meier analysis compared overall survival (OS) and progression-free survival (PFS) in patients with GERD vs without GERD (SSc and SSc-ILD), and PPI vs no PPI use (SSc-ILD only). Progression was defined as a decrease in either percentage predicted forced vital capacity of ≥10% or single-breath diffusing capacity for carbon monoxide of ≥15%, or death. Results It was found that 2693/4306 (63%) registered patients with SSc and 1204 / 1931 (62%) with SSc-ILD had GERD. GERD was not associated with decreased OS or decreased PFS in patients in either cohort. In SSc-ILD, PPI use was associated with improved OS vs no PPI use after 1 year [98.4% (95% CI: 97.6, 99.3); n  = 760 vs 90.8% (87.9–93.8); n  = 290] and after 5 years [91.4% (89.2–93.8); n  = 357 vs 70.9% (65.2–77.1); n  = 106; P  < 0.0001]. PPI use was also associated with improved PFS vs no PPI use after 1 year [95.9% (94.6–97.3); n  = 745 vs 86.4% (82.9–90.1); n  = 278] and after 5 years [66.8% (63.0–70.8); n  = 286 vs 45.9% (39.6–53.2); n  = 69; P  < 0.0001]. Conclusion GERD had no effect on survival in SSc or SSc-ILD. PPIs improved survival in patients with SSc-ILD. Controlled, prospective trials are needed to confirm this finding. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. So behandele ich Patienten, die eine DMARD-Therapie benötigen und eine MGUS haben.

Author

Strunz, Patrick-Pascal and Schmalzing, Marc

Abstract

Copyright of Zeitschrift für Rheumatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

39. Paraneoplastische Syndrome in der Rheumatologie.

Author

Strunz, Patrick-Pascal and Schmalzing, Marc

Abstract

Copyright of Zeitschrift für Rheumatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

42. CMR detects extensive intracavitary thrombi as solitary clinical presentation of Antiphospholipid Syndrome: A case report.

Author

Reiter, Theresa, Demirbas, Senem, Schmalzing, Marc, Voelker, Wolfram, Bauer, Wolfgang R., and Güder, Gülmisal

Subjects
CARDIAC magnetic resonance imaging, SYMPTOMS
Abstract

Intracavitary thrombi are an important differential diagnosis of cardiac masses. Cardiac magnetic resonance imaging (CMR) allows their non‐invasive characterization. This case highlights extensive cardiac thrombi detected by CMR as solitary presentation of antiphospholipid syndrome. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Management von entzündlich rheumatischen Erkrankungen während und nach Malignomen.

Author

Schmalzing, Marc

Abstract

Copyright of Zeitschrift für Rheumatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022
Full Text
View/download PDF

45. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis

Author

Moinzadeh, Pia, Aberer, Elisabeth, Ahmadi-Simab, Keihan, Blank, Norbert, Distler, Joerg H W, Fierlbeck, Gerhard, Genth, Ekkehard, Guenther, Claudia, Hein, Ruediger, Henes, Joerg, Herich, Lena, Herrgott, Ilka, Koetter, Ina, Kreuter, Alexander, Krieg, Thomas, Kuhr, Kathrin, Lorenz, Hanns-Martin, Meier, Florian, Melchers, Inga, Mensing, Hartwig, Mueller-Ladner, Ulf, Pfeiffer, Christiane, Riemekasten, Gabriela, Sárdy, Miklós, Schmalzing, Marc, Sunderkoetter, Cord, Susok, Laura, Tarner, Ingo H, Vaith, Peter, Worm, Margitta, Wozel, Gottfried, Zeidler, Gabriele, Hunzelmann, Nicolas, Ahrazoglu, Nil Mona, Becker, Mike Oliver, Mierau, Rudolf, Neeck, Gunther, Fiehn, Christoph, Juche, Aaron, Rubbert, Andrea, Weber, Manfred, Fischer-Betz, Rebecca, Sticherling, Michael, Burkhardt, Harald, Koehm, Michaela, Seitz, Cornelia S, Herink, Claudia, Foeldvári, Ivan, Norgauer, Johannes, Schoeffel, Dieter, Renner, Regina, Ziemer, Mirjana, Steinbrink, Kerstin, Stadler, Rudolf, Müller, Verena, Ziai, Mahzad, Karrer, Sigrid, Landthaler, Michael, Meyringer, Rotraud, Buslau, Michael, Tomsitz, Dirk, Lee, Hae- Hyuk, Lehmann, Percy, Gaebelein-Wissing, Noemi, Wagner, Marieke, Ebel, Joachim, Beyer, Christian, Varga, Rita, Bretterklieber, Agnes, Reichenberger, Frank, and Himsel, Andrea

Published
2015
Full Text
View/download PDF

47. Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial

Author

van Laar, Jacob M., Farge, Dominique, Sont, Jacob K., Naraghi, Kamran, Marjanovic, Zora, Larghero, Jérôme, Schuerwegh, Annemie J., Marijt, Erik W. A., Vonk, Madelon C., Schattenberg, Anton V., Matucci-Cerinic, Marco, Voskuyl, Alexandre E., van de Loosdrecht, Arjan A., Daikeler, Thomas, Kötter, Ina, Schmalzing, Marc, Martin, Thierry, Lioure, Bruno, Weiner, Stefan M., Kreuter, Alexander, Deligny, Christophe, Durand, Jean-Marc, Emery, Paul, Machold, Klaus P., Sarrot-Reynauld, Francoise, Warnatz, Klaus, Adoue, Daniel F. P., Constans, Joël, Tony, Hans-Peter, Del Papa, Nicoletta, Fassas, Athanasios, Himsel, Andrea, Launay, David, Lo Monaco, Andrea, Philippe, Pierre, Quéré, Isabelle, Rich, Éric, Westhovens, Rene, Griffiths, Bridget, Saccardi, Riccardo, van den Hoogen, Frank H., Fibbe, Willem E., Socié, Gérard, Gratwohl, Alois, and Tyndall, Alan

Published
2014
Full Text
View/download PDF

49. Präoperative Anämie beim Rheumatiker.

Author

Böhm, Lena, Schmalzing, Marc, and Meybohm, Patrick

Abstract

Copyright of Zeitschrift für Rheumatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results